Photo from wikipedia
In the ARTEMIS-CTONG1509 multicenter phase 3 study recently published in Cancer Cell, Zhou et al. investigate the combination of the EGFR tyrosine kinase inhibitor (TKI) erlotinib and antiangiogenic bevacizumab in… Click to show full abstract
In the ARTEMIS-CTONG1509 multicenter phase 3 study recently published in Cancer Cell, Zhou et al. investigate the combination of the EGFR tyrosine kinase inhibitor (TKI) erlotinib and antiangiogenic bevacizumab in treatment-naive Chinese patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). The primary endpoint of progression-free survival (PFS) was significantly extended from 11.2 months with erlotinib monotherapy to 17.9 months with the combination.
Keywords:
egfr mutant;
line anti;
vegf plus;
anti vegf;
tki;
first line
Journal Title: Signal Transduction and Targeted Therapy
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Signal Transduction and Targeted Therapy
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!